Showing results (401-410 of 569) with videos related to

Sort By:
Pageof 57
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416B C Kuenen, M Levi, J C M Meijers, et al.
Biochemical Pharmacology|March 26, 2002
A doxorubicin-CNGRC-peptide conjugate with prodrug propertiesYvette van Hensbergen, Henk J Broxterman, Yvonne W Elderkamp, et al.
International Journal of Cancer|May 29, 1997
Expression of drug resistance proteins in breast cancer, in relation to chemotherapyS C Linn, H M Pinedo, J van Ark-Otte, et al.
Journal of Chemotherapy (Florence, Italy)|July 26, 2005
Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicityG Codacci-Pisanelli, H M Pinedo, J Lankelma, et al.
American Journal of Clinical Pathology|February 1, 1997
Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancerA H Honkoop, H M Pinedo, J S De Jong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumorsG Giaccone, S C Linn, J Welink, et al.
Journal of the National Cancer Institute|December 20, 1989
Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cellsG J Schuurhuis, H J Broxterman, A Cervantes, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 1995
Thymidylate synthase and drug resistanceG J Peters, C L van der Wilt, B van Triest, et al.
Cancer Research|June 1, 1996
Inheritance of abnormal expression of SOS-like response in xeroderma pigmentosum and hereditary cancer-prone syndromesP J Abrahams, A Houweling, D M Cornelissen-Steijger, et al.
Pageof 57